MARKET

IPCIF

IPCIF

Intellipharmaceu
OTCMQB

Real-time Quotes | Nasdaq Last Sale

0.107
-0.019
-14.88%
Closed 10:57 05/18 EDT
OPEN
0.119
PREV CLOSE
0.107
HIGH
0.119
LOW
0.107
VOLUME
26.50K
TURNOVER
3.09K
52 WEEK HIGH
0.300
52 WEEK LOW
0.080
MARKET CAP
3.54M
P/E (TTM)
-0.6688
1D
5D
1M
3M
1Y
5Y
Intellipharmaceutics Announces First Quarter 2022 Results
TORONTO, ON / ACCESSWIRE / April 14, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and gene...
ACCESSWIRE · 04/14 20:30
-- Earnings Flash (IPCIF) INTELLIPHARMACEUTICS INTERNATIONAL Reports Q1 Loss $-0.03
MT Newswires · 04/14 16:48
Intellipharmaceutics Announces Fiscal Year 2021 Results
TORONTO, ON / ACCESSWIRE / February 28, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and gen...
ACCESSWIRE · 02/28 22:25
Intellipharmaceutics Reports Director Election Results
TORONTO, ON / ACCESSWIRE / February 4, 2022 / Intellipharmaceutics International Inc. The voting results, as set out in the scrutineer's report for the Meeting, were as follows:Name of NomineeVotes ForVotes Withheld Dr.
ACCESSWIRE · 02/04 21:35
Intellipharmaceutics Mourns the Death of Valued Board Member Kenneth Eugene Keirstead
TORONTO, ON / ACCESSWIRE / January 13, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and ge...
ACCESSWIRE · 01/13 22:20
Intellipharmaceutics Comments on Recent Trading Activity
TORONTO, ON / ACCESSWIRE / December 22, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and gen...
ACCESSWIRE · 12/22/2021 18:00
Intellipharmaceutics International reports Q1 results
Intellipharmaceutics International (IPCIF): Q1 GAAP EPS of -$0.04.Cash balance of $202.67K.Press Release
Seekingalpha · 04/14/2021 11:51
Intellipharmaceutics International reports FY results
Intellipharmaceutics International (IPCIF): FY GAAP EPS of -$0.14.Revenue of $1.4M (-59.8% Y/Y)Press Release
Seekingalpha · 03/01/2021 14:28
More
No Data
Learn about the latest financial forecast of IPCIF. Analyze the recent business situations of Intellipharmaceu through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
100.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average IPCIF stock price target is 25.00 with a high estimate of 25.00 and a low estimate of 25.00.
High25.00
Average25.00
Low25.00
Current 0.1070
EPS
Actual
Estimate
-0.48-0.36-0.24-0.12
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q1 2019
Institutional Holdings
Institutions: 5
Institutional Holdings: 46.72K
% Owned: 0.14%
Shares Outstanding: 33.09M
TypeInstitutionsShares
Increased
0
0
New
2
30.01K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
No Data
About IPCIF
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.

Webull offers kinds of IntelliPharmaCeutics Intl Inc (USA) stock information, including OTCMQB:IPCIF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPCIF stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IPCIF stock methods without spending real money on the virtual paper trading platform.